Iovance Biotherapeutics Appoints Athena Countouriotis, M.D., to Board of Directors
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: GlobeNewswire
SAN CARLOS, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Athena Countouriotis, M.D., to the company’s Board of Directors, effective June 10, 2019. Dr. Countouriotis is the President and Chief Executive Officer of Turning Point Therapeutics and specialized in hematology and oncology in her professional career. “Dr. Countouriotis has a long record of successful leadership in oncology drug development, and particular expertise in bringing novel therapies through clinical development,” commented Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “We are delighted to expand our Board with new members with deep drug development experience.” “I am excited to join the board at such an important time for the company following the strong data shown
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? [Yahoo! Finance]Yahoo! Finance
- Enrich Biosystems Welcomes Dr. Laszlo Radvanyi as Scientific Advisor [Yahoo! Finance]Yahoo! Finance
- Enrich Biosystems Welcomes Dr. Laszlo Radvanyi as Scientific AdvisorPR Web
- Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target lowered by analysts at Truist Financial Co. from $25.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
IOVA
Earnings
- 2/27/25 - Beat
IOVA
Sec Filings
- 3/7/25 - Form 4
- 3/7/25 - Form 4
- 3/7/25 - Form 4
- IOVA's page on the SEC website